Home/Filings/4/0001455244-10-000034
4//SEC Filing

Kalnik Matthew W. 4

Accession 0001455244-10-000034

CIK 0000072444other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 7:50 PM ET

Size

10.9 KB

Accession

0001455244-10-000034

Insider Transaction Report

Form 4
Period: 2010-03-02
Kalnik Matthew W.
SVP Strategic Plan. & Bus. Ops
Transactions
  • Other

    Common Stock

    2009-11-30$2.41/sh+5,404.282$13,00039,523.104 total
  • Exercise/Conversion

    Common Stock

    2010-03-02$3.95/sh+2,250$8,88841,773.104 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2010-03-022,25015,750 total
    Exercise: $3.95Exp: 2015-04-01Common Stock (2,250 underlying)
  • Sale

    Common Stock

    2010-03-02$5.45/sh2,250$12,26339,523.104 total
Footnotes (3)
  • [F1]Voluntarily reported acquisition under the Issuer's Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3.
  • [F2]The acquisition and sale of 2,250 shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  • [F3]One-quarter of this Option became exercisable on April 1, 2009. The remaining three-quarters of the Option will become exercisable in three equal installments on April 1, 2010, April 1, 2011 and April 1, 2012.

Issuer

NABI BIOPHARMACEUTICALS

CIK 0000072444

Entity typeother

Related Parties

1
  • filerCIK 0001459477

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 7:50 PM ET
Size
10.9 KB